Skip to main content
Signal8
Launch Terminal

Galmed Pharmaceuticals Ltd. (EOCN)

Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Sector: Pharmaceutical Preparations

Industry: Medical - Pharmaceuticals

Eocene Ltd. logo

Eocene Ltd.

NASDAQ:EOCNHealthcare
+3.96%$3.15
Mkt Cap$3.36M
Float792K
O/S1.07M
Inst Own14.6%
SI0.9%
Dilution
Eocene Ltd. logoNASDAQ:EOCN$3.15+3.96%
FormDescription
6-K
Foreign Private Issuer Report
4
6-K
Foreign Private Issuer Report
3
EFFECT
Notice of Effectiveness
2
6-K
Foreign Private Issuer Report
POS AM
Post-Effective Amendment
7
6-K
Foreign Private Issuer Report
6
6-K
Foreign Private Issuer Report
1
6-K/A
Foreign Private Issuer Report (Amended)
5
6-K
Foreign Private Issuer Report
3
6-K
Foreign Private Issuer Report
4
6-K
Foreign Private Issuer Report
2
6-K
Foreign Private Issuer Report
3
6-K
Foreign Private Issuer Report
2
6-K
Foreign Private Issuer Report
3
6-K
Foreign Private Issuer Report
2
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
7
424B3
Prospectus
3
6-K
Foreign Private Issuer Report
2
POS EX
SEC Filing
424B3
Prospectus
4
6-K
Foreign Private Issuer Report
4
6-K
Foreign Private Issuer Report
3
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report

1-25 of 381

…
    Galmed Pharmaceuticals Ltd. (EOCN) SEC Filings: 10-K, 10-Q, 8-K, Form 4 | Signal8